Kymab raises €94m for mAb pipelineUK-based biopharma group Kymab has brought a new backer from China on board. With the help from ORI Healthcare Fund, Kymab secured a US$100m Series C financing. more ➔
Proteros inks US$167m oncology pact with M...Proteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncolog … more ➔
Running made by biotechAdidas has presented the worlds first lightweight racing shoe made by recombinantly produced silk fibers. more ➔
Medigene offers neoantigen-specific TCRs Until mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the … more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
